½ÃÀ庸°í¼­
»óǰÄÚµå
1446908

¼¼°èÀÇ »çÀÌŬ·Îµ¦½ºÆ®¸° ½ÃÀå : À¯Çüº°, ÃÖÁ¾ »ç¿ëÀÚ »ê¾÷º° ±âȸ ºÐ¼® ¹× »ê¾÷ ¿¹Ãø(2023-2032³â)

Cyclodextrin Market By Type (Alpha-Cyclodextrin, Beta-Cyclodextrin, Gamma-Cyclodextrin), By End-User Industry (Food, Pharmaceutical, Cosmetics and Personal Care, Chemical, Textile, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Allied Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 354 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ »çÀÌŬ·Îµ¦½ºÆ®¸°(½ÃŬ·Îµ¦½ºÆ®¸°, Cyclodextrin) ½ÃÀåÀº 2022³â¿¡ 3¾ï 3,400¸¸ ´Þ·¯·Î Æò°¡µÇ¾î 2023³âºÎÅÍ 2032³â¿¡ °ÉÃÄ 5.7%ÀÇ CAGR·Î ÃßÀÌÇÏ¸ç ¼ºÀå ÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2032³â¿¡´Â 5¾ï 7,960¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ÃßÁ¤µÇ°í ÀÖ½À´Ï´Ù.

Cyclodextrin Market-IMG1

»çÀÌŬ·Îµ¦½ºÆ®¸°Àº ¾ËÆÄ-1,4-±Û¸®ÄÚ½Ãµå °áÇÕÀ¸·Î ¿¬°áµÈ Æ÷µµ´ç ´ÜÀ§·Î ±¸¼ºµÈ °í¸®Çü ¿Ã¸®°í´çÀÔ´Ï´Ù. ÀÌ ºÐÀÚ´Â µ¶Æ¯ÇÑ ¿øÈ¯ ¶Ç´Â À߸° ¿ø»Ô ±¸Á¶¸¦ °¡Áö°í ÀÖÀ¸¸ç, ¼Ò¼ö¼º Áß¾Ó °øµ¿°ú Ä£¼ö¼º ¿ÜºÎ Ç¥¸éÀÌ Æ¯Â¡ÀÔ´Ï´Ù. »çÀÌŬ·Îµ¦½ºÆ®¸°Àº ´Ù¸¥ ºÐÀÚ¿Í ºÀÀÔ º¹ÇÕü¸¦ Çü¼ºÇÏ¿© °Ô½ºÆ® ºÐÀÚ¸¦ Áß¾Ó °øµ¿ ³»¿¡ ĸ½¶È­ÇÒ ¼ö ÀÖ´Â ´É·ÂÀ¸·Î Àß ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ¯¼º ´öºÐ¿¡ »çÀÌŬ·Îµ¦½ºÆ®¸°Àº Á¦¾à, ½Äǰ, È­Àåǰ µî ´Ù¾çÇÑ »ê¾÷¿¡¼­ ´Ù¾çÇÑ È­ÇÕ¹°ÀÇ ¿ëÇØµµ, ¾ÈÁ¤¼º ¹× »ýü ÀÌ¿ë·üÀ» °³¼±ÇÏ´Â µîÀÇ ¿ëµµ·Î À¯¿ëÇÏ°Ô »ç¿ëµË´Ï´Ù.

Áö¼Ó °¡´É¼º ¹× ģȯ°æ È­ÇÐ °üÇà¿¡ ´ëÇÑ °­Á¶°¡ Ä¿Áö´Â °Íµµ »çÀÌŬ·Îµ¦½ºÆ®¸° ½ÃÀåÀÇ ¶Ç ´Ù¸¥ ¿øµ¿·ÂÀÔ´Ï´Ù. »çÀÌŬ·Îµ¦½ºÆ®¸°Àº »ýºÐÇØ¼ºÀ̸ç ȯ°æ ģȭÀûÀ̱⠶§¹®¿¡ ģȯ°æÀûÀÎ ´ë¾ÈÀÌ ¿ì¼±½ÃµÇ´Â ÀÀ¿ë ºÐ¾ß¿¡ ÀûÇÕÇÕ´Ï´Ù. ±âÁ¸ È­ÇÐ ¹°Áú ´ë½Å »çÀÌŬ·Îµ¦½ºÆ®¸°À» »ç¿ëÇÏ´Â °ÍÀº Áö¼Ó °¡´ÉÇÑ °üÇàÀ» ÇâÇÑ Àü ¼¼°èÀûÀÎ Ãß¼¼¿¡ ºÎÇÕÇϸç, ȯ°æÀ» °í·ÁÇÑ ¼Ö·ç¼ÇÀ» ã´Â ¾÷°è¿¡ ¸Å·ÂÀûÀ¸·Î ´Ù°¡¿É´Ï´Ù.

¶ÇÇÑ ´Ù¾çÇÑ »ê¾÷ ºÐ¾ß¿¡¼­ ÁøÇà ÁßÀÎ ¿¬±¸ °³¹ß Ȱµ¿µµ »çÀÌŬ·Îµ¦½ºÆ®¸° ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¿¬±¸ÀÚµéÀº »çÀÌŬ·Îµ¦½ºÆ®¸°ÀÇ °íÀ¯ÇÑ Æ¯¼ºÀ» Ȱ¿ëÇÏ´Â »õ·Î¿î ÀÀ¿ë ºÐ¾ß¿Í Á¦ÇüÀ» ¸ð»öÇϰí ÀÖ½À´Ï´Ù. ¿©±â¿¡´Â »õ·Î¿î ¾à¹° Àü´Þ ½Ã½ºÅÛ, °³¼±µÈ ĸ½¶È­ ±â¼ú, ³ó¾÷ ¹× ¼¶À¯¿Í °°Àº ºÐ¾ß¿¡¼­ÀÇ Çõ½ÅÀûÀÎ ¿ëµµ°¡ Æ÷ÇԵ˴ϴÙ. »õ·Î¿î ÀÀ¿ë ºÐ¾ßÀÇ Áö¼ÓÀûÀÎ ¹ß°ß°ú µ¶Á¡ÀûÀÎ Á¦Çü °³¹ßÀº »çÀÌŬ·Îµ¦½ºÆ®¸°¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

±×·¯³ª ±ÔÁ¦ °í·Á »çÇ×µµ »çÀÌŬ·Îµ¦½ºÆ®¸° ½ÃÀå¿¡ ¿µÇâÀ» ¹ÌĨ´Ï´Ù. »çÀÌŬ·Îµ¦½ºÆ®¸°Àº Á¦¾à ¹× ½ÄǰÀ» ºñ·ÔÇÑ ´Ù¾çÇÑ ¿ëµµ·Î »ç¿ëµÇ±â ¶§¹®¿¡ ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°ÇÀ» ÁؼöÇÏ´Â °ÍÀÌ Áß¿äÇÕ´Ï´Ù. »çÀÌŬ·Îµ¦½ºÆ®¸° ÇÔÀ¯ Á¦Ç°¿¡ ´ëÇÑ ±ÔÁ¦ ½ÂÀÎÀ» ȹµæÇÏ´Â µ¥´Â ¸¹Àº ½Ã°£°ú ºñ¿ëÀÌ ¼Ò¿äµÉ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÁøÈ­ÇÏ´Â ±ÔÁ¦ ȯ°æ°ú ±ÔÁ¤ Áؼö Ç¥ÁØÀÇ º¯È­·Î ÀÎÇØ Á¦Á¶¾÷ü´Â Áö¼ÓÀûÀÎ ÀûÀÀÀÌ ÇÊ¿äÇÒ ¼ö ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå¿¡ º¹À⼺À» ´õÇÒ ¼ö ÀÖ½À´Ï´Ù.

¹Ý´ë·Î ½ÄÀ½·á ºÎ¹®¿¡¼­´Â »çÀÌŬ·Îµ¦½ºÆ®¸°ÀÌ Ä¸½¶È­Á¦, Çâ·á °³·®Á¦, ¾ÈÁ¤Á¦ µîÀ¸·Î Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¦Ç°Àº Á¦Ç°ÀÇ Ç°Áú, ¸À, À¯Åë±âÇÑÀ» °³¼±ÇÏ´Â µ¥ ±â¿©ÇÕ´Ï´Ù. ¼ÒºñÀÚµéÀÌ Á¡Á¡ ´õ °Ç°­Çϰí ÀÚ¿¬ÀûÀÎ Àç·á¸¦ ã°Ô µÇ¸é¼­, ¿øÄ¡ ¾Ê´Â ¸À°ú ³¿»õ¸¦ °¡¸± ¼ö ÀÖ´Â »çÀÌŬ·Îµ¦½ºÆ®¸°Àº ½Äǰ Á¦Á¶¾÷ü¿¡°Ô ¸Å¿ì ±ÍÁßÇÑ Á¸Àç°¡ µÇ¾ú½À´Ï´Ù. Ŭ¸° ¶óº§ Á¦Ç°¿¡ ´ëÇÑ Ãß¼¼¿Í ±â´É¼º ½Äǰ¿¡ ´ëÇÑ ¼ö¿ä´Â ÀÌ ½ÃÀå ºÎ¹®ÀÇ ±âȸ¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

»çÀÌŬ·Îµ¦½ºÆ®¸° ½ÃÀåÀº À¯Çü, ÃÖÁ¾ »ç¿ëÀÚ »ê¾÷ ¹× Áö¿ª¿¡ µû¶ó ºÐ·ùµË´Ï´Ù. À¯Çüº°·Î ½ÃÀåÀº ¾ËÆÄ-»çÀÌŬ·Îµ¦½ºÆ®¸°, º£Å¸-»çÀÌŬ·Îµ¦½ºÆ®¸°, °¨¸¶-»çÀÌŬ·Îµ¦½ºÆ®¸°À¸·Î ºÐ·ùµË´Ï´Ù. ÃÖÁ¾ »ç¿ëÀÚ »ê¾÷ ±â¹ÝÀº ½Äǰ, ÀǾàǰ, È­Àåǰ ¹× °³ÀÎ °ü¸®, È­ÇÐ, ¼¶À¯ ¹× ±âŸ·Î ³ª´­ ¼ö ÀÖ½À´Ï´Ù. Áö¿ªº°·Î ½ÃÀåÀº ºÏ¹Ì, À¯·´, ¾Æ½Ã¾Æ ÅÂÆò¾ç, LAMEA·Î ±¸ºÐÇÏ¿© Á¶»çÇß½À´Ï´Ù.

ÀÌÇØ°ü°èÀÚ¸¦ À§ÇÑ ÁÖ¿ä ÀÌÁ¡

  • º» º¸°í¼­¿¡¼­´Â 2022³âºÎÅÍ 2032³â±îÁöÀÇ »çÀÌŬ·Îµ¦½ºÆ®¸° ½ÃÀå ºÐ¼® ½ÃÀå ºÎ¹®, ÇöÀç µ¿Çâ, ÃßÁ¤¡¤µ¿Çâ, ¿ªÇÐÀ» Á¤·®ÀûÀ¸·Î ºÐ¼®ÇÏ¿© À¯·ÂÇÑ »çÀÌŬ·Îµ¦½ºÆ®¸° ½ÃÀå ±âȸ¸¦ ƯÁ¤ÇÕ´Ï´Ù.
  • ½ÃÀå ¼ºÀå ÃËÁø ¿äÀÎ, ½ÃÀå ¼ºÀå ¾ïÁ¦ ¿äÀÎ, ½ÃÀå ±âȸ¿Í °ü·ÃµÈ Á¤º¸¿Í ÇÔ²² ½ÃÀå Á¶»ç¸¦ Á¦°øÇÕ´Ï´Ù.
  • Porter's Five Forces ºÐ¼®Àº ÀÌÇØ°ü°èÀÚµéÀÌ ÀÌÀÍ¿¡ ÁßÁ¡À» µÐ ºñÁî´Ï½º °áÁ¤À» ³»¸®°í °ø±Þ¾÷ü¿Í ±¸¸ÅÀÚÀÇ ³×Æ®¿öÅ©¸¦ °­È­ÇÒ ¼ö ÀÖµµ·Ï ±¸¸ÅÀÚ¿Í °ø±Þ¾÷üÀÇ ÀáÀç·ÂÀ» º¸¿©ÁÝ´Ï´Ù.
  • »çÀÌŬ·Îµ¦½ºÆ®¸° ½ÃÀåÀÇ ¼¼ºÐÈ­¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ ºÐ¼®Àº ½ÃÀå ±âȸ¸¦ °áÁ¤ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.
  • °¢ Áö¿ªÀÇ ÁÖ¿ä ±¹°¡¸¦ ¼¼°è ½ÃÀå¿¡ ´ëÇÑ ¸ÅÃ⠱⿩µµ¿¡ µû¶ó ¸ÅÇÎÇÕ´Ï´Ù.
  • ½ÃÀå ±â¾÷ Æ÷Áö¼Å´×Àº º¥Ä¡¸¶Å·À» ¿ëÀÌÇÏ°Ô ÇÏ°í ½ÃÀå ±â¾÷ÀÇ ÇöÀç À§Ä¡¸¦ ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.
  • ÀÌ º¸°í¼­¿¡´Â Áö¿ªº° ¹× ¼¼°è »çÀÌŬ·Îµ¦½ºÆ®¸° ½ÃÀå µ¿Çâ, ÁÖ¿ä ±â¾÷, ½ÃÀå ºÎ¹®, ÀÀ¿ë ºÐ¾ß ¹× ½ÃÀå ¼ºÀå Àü·« ºÐ¼®ÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­¿¡¼­ °¡´ÉÇÑ ¸ÂÃã¼³Á¤(Ãß°¡ ºñ¿ë ¹× ÀÏÁ¤ ÇÊ¿ä)

  • Á¦Á¶ ¿ª·®
  • ÅõÀÚ ±âȸ
  • °ø±Þ¸Á ºÐ¼® ¹× º¥´õ ¸¶Áø
  • ±â¼ú µ¿Ç⠺м®
  • Á¦Ç°/ºÎ¹®º° ±â¾÷ ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • ÁÖ¿ä ±â¾÷ÀÇ ½ÅÁ¦Ç° °³¹ß/Á¦Ç° ¸ÅÆ®¸¯½º
  • ±¹°¡, Áö¿ª, ¼¼°è ¼öÁØÀÇ °í°´/¿ªÇÐ µ¥ÀÌÅÍ
  • ±ÔÁ¦ °¡À̵å¶óÀÎ
  • °í°´ÀÇ °ü½É¿¡ µû¸¥ Ãß°¡ ±â¾÷ °³¿ä
  • ±¹°¡º° ¶Ç´Â Áö¿ªº° Ãß°¡ ºÐ¼®-½ÃÀå ±Ô¸ð ¹× ¿¹Ãø
  • È®ÀåµÈ ±â¾÷ °³¿ä ¸ñ·Ï
  • °ú°Å ½ÃÀå µ¥ÀÌÅÍ
  • ¼öÃâÀÔ ºÐ¼®/µ¥ÀÌÅÍ
  • ÁÖ¿ä ±â¾÷ÀÇ »ó¼¼(¼ÒÀçÁö, ¿¬¶ôó, °ø±Þ¾÷ü/º¥´õ ³×Æ®¿öÅ© µîÀ» Æ÷ÇÔÇÑ ¿¢¼¿ Çü½Ä)
  • ±Û·Î¹ú/Áö¿ª/±¹°¡ ¼öÁØ¿¡¼­ Ç÷¹À̾îÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®
  • SWOT ºÐ¼®
  • ¼ö·® ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå °³¿ä

  • ½ÃÀå Á¤ÀÇ ¹× ¹üÀ§
  • ÁÖ¿ä Á¶»ç °á°ú
    • ¿µÇâ ¿äÀÎ
    • ÁÖ¿ä ÅõÀÚ ±âȸ
  • Porter's Five Forces ºÐ¼®
  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø ¿äÀÎ
    • ¾ïÁ¦ ¿äÀÎ
    • ±âȸ
  • ¹ë·ùüÀÎ ºÐ¼®
  • °¡°Ý ºÐ¼®
  • ÁÖ¿ä ±ÔÁ¦ ºÐ¼®
  • ƯÇã »óȲ

Á¦4Àå »çÀÌŬ·Îµ¦½ºÆ®¸° ½ÃÀå : À¯Çüº°

  • °³¿ä
  • ¥á-»çÀÌŬ·Îµ¦½ºÆ®¸°
  • ¥â-»çÀÌŬ·Îµ¦½ºÆ®¸°
  • ¥ã-»çÀÌŬ·Îµ¦½ºÆ®¸°

Á¦5Àå »çÀÌŬ·Îµ¦½ºÆ®¸° ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚ »ê¾÷º°

  • °³¿ä
  • ½Äǰ
  • ÀǾàǰ
  • È­Àåǰ ¹× ÆÛ½º³ÎÄɾî
  • È­ÇÐ
  • ¼¶À¯
  • ±âŸ

Á¦6Àå »çÀÌŬ·Îµ¦½ºÆ®¸° ½ÃÀå : Áö¿ªº°

  • °³¿ä
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ
  • ¾Æ½Ã¾Æ ÅÂÆò¾ç
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • È£ÁÖ
    • ±âŸ
  • ³²¹Ì, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«(LAMEA)
    • ºê¶óÁú
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ

Á¦7Àå °æÀï ±¸µµ

  • ¼Ò°³
  • ÁÖ¿ä ¼º°ø Àü·«
  • ÁÖ¿ä 10°³»çÀÇ Á¦Ç° ¸ÅÇÎ
  • °æÀï ´ë½Ãº¸µå
  • °æÀï È÷Æ®¸Ê
  • ÁÖ¿ä ±â¾÷ÀÇ Æ÷Áö¼Å´×(2022³â)

Á¦8Àå ±â¾÷ °³¿ä

  • Cayman Chemical Company
  • Cambrex Corporation
  • Wellona Pharma Private Limited.
  • Wacker Chemie AG.
  • Cyclolab
  • Tocopharm Co. Limited
  • Roquette Freres
  • Midas Pharma GmbH
  • Ligand Pharmaceuticals Incorporated
  • Cyclo Therapeutics, Inc
LYJ 24.03.28

The global cyclodextrin market was valued at $334.0 million in 2022 and is estimated to reach $579.6 million by 2032, exhibiting a CAGR of 5.7% from 2023 to 2032.

Cyclodextrin Market - IMG1

Cyclodextrins are cyclic oligosaccharides composed of glucose units linked by alpha-1,4-glycosidic bonds. These molecules have a unique torus or truncated cone structure, characterized by a hydrophobic central cavity and a hydrophilic outer surface. Cyclodextrins are known for their ability to form inclusion complexes with other molecules, where the guest molecule can be encapsulated within their central cavity. This property makes cyclodextrins useful in various industries, including pharmaceuticals, food, cosmetics, and more, for applications such as improving the solubility, stability, and bioavailability of different compounds.

The growing emphasis on sustainability and green chemistry practices is another driving force for the cyclodextrin market. Cyclodextrins are biodegradable and environmentally friendly, making them attractive for applications where eco-friendly alternatives are prioritized. The use of cyclodextrins in place of traditional chemicals aligns with the global push towards sustainable practices, appealing to industries seeking environmentally conscious solutions.

Moreover, ongoing research and development activities in various industries contribute to the expansion of the cyclodextrin market. Researchers are exploring new applications and formulations that leverage the unique properties of cyclodextrins. This includes novel drug delivery systems, improved encapsulation techniques, and innovative uses in areas such as agriculture and textiles. The continuous discovery of novel applications and the development of proprietary formulations drive the demand for cyclodextrins.

However, regulatory considerations also impact the cyclodextrin market. As cyclodextrins are used in various applications, including pharmaceuticals and food products, adherence to stringent regulatory requirements is crucial. Obtaining regulatory approvals for cyclodextrin-containing products can be time-consuming and expensive. Additionally, evolving regulatory landscapes and changes in compliance standards may require continuous adaptation by manufacturers, adding a layer of complexity to the market.

On the contrary, in the food and beverage sector, cyclodextrins find applications as encapsulating agents, flavor modifiers, and stabilizers. They contribute to improved product quality, taste, and shelf life. As consumers increasingly seek healthier and more natural ingredients, cyclodextrins, with their ability to mask undesirable flavors and odors, become invaluable for food manufacturers. The trend towards clean-label products and the demand for functional foods further drive the opportunities in this market segment.

The cyclodextrin market is segmented on the basis of type, end-user industry, and region. On the basis of type, the market is categorized into alpha-cyclodextrin, beta-cyclodextrin, and gamma-cyclodextrin. On the basis of end-user industry, it is divided into food, pharmaceutical, cosmetics & personal care, chemical, textile, and others. Region-wise, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.

The global cyclodextrin market profiles leading players that include Cambrex Corporation, Cayman Chemical, Wellona Pharma, Wacker Chemie AG, Cyclolab, Tocopharm Co. Limited, Roquette Freres, Midas Pharma GmbH, Ligand Pharmaceuticals Incorporated, and Cyclo Therapeutics, Inc.

Other key players involved in the manufacturing of cyclodextrin includes Zibo Qianhui biological technology co., ltd, Xi'an Deli Biochemical Industry Co., Ltd, Merck KgaA, Otto Chemie Pvt. Ltd., VIO CHEMICALS, Ashland, and TCI Chemicals Pvt. Ltd. The global cyclodextrin market report provides in-depth competitive analysis as well as profiles of these major players.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the cyclodextrin market analysis from 2022 to 2032 to identify the prevailing cyclodextrin market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the cyclodextrin market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global cyclodextrin market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Manufacturing Capacity
  • Investment Opportunities
  • Supply Chain Analysis & Vendor Margins
  • Technology Trend Analysis
  • Market share analysis of players by products/segments
  • New Product Development/ Product Matrix of Key Players
  • Patient/epidemiology data at country, region, global level
  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Import Export Analysis/Data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)
  • Market share analysis of players at global/region/country level
  • SWOT Analysis
  • Volume Market Size and Forecast

Key Market Segments

By Type

  • Alpha-Cyclodextrin
  • Beta-Cyclodextrin
  • Gamma-Cyclodextrin

By End-User Industry

  • Food
  • Pharmaceutical
  • Cosmetics and Personal Care
  • Chemical
  • Textile
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Cayman Chemical Company
    • Cambrex Corporation
    • Wellona Pharma Private Limited.
    • Wacker Chemie AG.
    • Cyclolab
    • Tocopharm Co. Limited
    • Roquette Freres
    • Midas Pharma GmbH
    • Ligand Pharmaceuticals Incorporated
    • Cyclo Therapeutics, Inc

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
  • 3.4. Market dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities
  • 3.5. Value Chain Analysis
  • 3.6. Pricing Analysis
  • 3.7. Key Regulation Analysis
  • 3.8. Patent Landscape

CHAPTER 4: CYCLODEXTRIN MARKET, BY TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Alpha-Cyclodextrin
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Beta-Cyclodextrin
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Gamma-Cyclodextrin
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: CYCLODEXTRIN MARKET, BY END-USER INDUSTRY

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Food
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Pharmaceutical
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Cosmetics and Personal Care
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country
  • 5.5. Chemical
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by region
    • 5.5.3. Market share analysis by country
  • 5.6. Textile
    • 5.6.1. Key market trends, growth factors and opportunities
    • 5.6.2. Market size and forecast, by region
    • 5.6.3. Market share analysis by country
  • 5.7. Others
    • 5.7.1. Key market trends, growth factors and opportunities
    • 5.7.2. Market size and forecast, by region
    • 5.7.3. Market share analysis by country

CHAPTER 6: CYCLODEXTRIN MARKET, BY REGION

  • 6.1. Overview
    • 6.1.1. Market size and forecast By Region
  • 6.2. North America
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by Type
    • 6.2.3. Market size and forecast, by End-User Industry
    • 6.2.4. Market size and forecast, by country
      • 6.2.4.1. U.S.
      • 6.2.4.1.1. Market size and forecast, by Type
      • 6.2.4.1.2. Market size and forecast, by End-User Industry
      • 6.2.4.2. Canada
      • 6.2.4.2.1. Market size and forecast, by Type
      • 6.2.4.2.2. Market size and forecast, by End-User Industry
      • 6.2.4.3. Mexico
      • 6.2.4.3.1. Market size and forecast, by Type
      • 6.2.4.3.2. Market size and forecast, by End-User Industry
  • 6.3. Europe
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by Type
    • 6.3.3. Market size and forecast, by End-User Industry
    • 6.3.4. Market size and forecast, by country
      • 6.3.4.1. Germany
      • 6.3.4.1.1. Market size and forecast, by Type
      • 6.3.4.1.2. Market size and forecast, by End-User Industry
      • 6.3.4.2. UK
      • 6.3.4.2.1. Market size and forecast, by Type
      • 6.3.4.2.2. Market size and forecast, by End-User Industry
      • 6.3.4.3. France
      • 6.3.4.3.1. Market size and forecast, by Type
      • 6.3.4.3.2. Market size and forecast, by End-User Industry
      • 6.3.4.4. Spain
      • 6.3.4.4.1. Market size and forecast, by Type
      • 6.3.4.4.2. Market size and forecast, by End-User Industry
      • 6.3.4.5. Italy
      • 6.3.4.5.1. Market size and forecast, by Type
      • 6.3.4.5.2. Market size and forecast, by End-User Industry
      • 6.3.4.6. Rest of Europe
      • 6.3.4.6.1. Market size and forecast, by Type
      • 6.3.4.6.2. Market size and forecast, by End-User Industry
  • 6.4. Asia-Pacific
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by Type
    • 6.4.3. Market size and forecast, by End-User Industry
    • 6.4.4. Market size and forecast, by country
      • 6.4.4.1. China
      • 6.4.4.1.1. Market size and forecast, by Type
      • 6.4.4.1.2. Market size and forecast, by End-User Industry
      • 6.4.4.2. India
      • 6.4.4.2.1. Market size and forecast, by Type
      • 6.4.4.2.2. Market size and forecast, by End-User Industry
      • 6.4.4.3. Japan
      • 6.4.4.3.1. Market size and forecast, by Type
      • 6.4.4.3.2. Market size and forecast, by End-User Industry
      • 6.4.4.4. South Korea
      • 6.4.4.4.1. Market size and forecast, by Type
      • 6.4.4.4.2. Market size and forecast, by End-User Industry
      • 6.4.4.5. Australia
      • 6.4.4.5.1. Market size and forecast, by Type
      • 6.4.4.5.2. Market size and forecast, by End-User Industry
      • 6.4.4.6. Rest of Asia-Pacific
      • 6.4.4.6.1. Market size and forecast, by Type
      • 6.4.4.6.2. Market size and forecast, by End-User Industry
  • 6.5. LAMEA
    • 6.5.1. Key market trends, growth factors and opportunities
    • 6.5.2. Market size and forecast, by Type
    • 6.5.3. Market size and forecast, by End-User Industry
    • 6.5.4. Market size and forecast, by country
      • 6.5.4.1. Brazil
      • 6.5.4.1.1. Market size and forecast, by Type
      • 6.5.4.1.2. Market size and forecast, by End-User Industry
      • 6.5.4.2. Saudi Arabia
      • 6.5.4.2.1. Market size and forecast, by Type
      • 6.5.4.2.2. Market size and forecast, by End-User Industry
      • 6.5.4.3. South Africa
      • 6.5.4.3.1. Market size and forecast, by Type
      • 6.5.4.3.2. Market size and forecast, by End-User Industry
      • 6.5.4.4. Rest of LAMEA
      • 6.5.4.4.1. Market size and forecast, by Type
      • 6.5.4.4.2. Market size and forecast, by End-User Industry

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top winning strategies
  • 7.3. Product mapping of top 10 player
  • 7.4. Competitive dashboard
  • 7.5. Competitive heatmap
  • 7.6. Top player positioning, 2022

CHAPTER 8: COMPANY PROFILES

  • 8.1. Cayman Chemical Company
    • 8.1.1. Company overview
    • 8.1.2. Key executives
    • 8.1.3. Company snapshot
    • 8.1.4. Operating business segments
    • 8.1.5. Product portfolio
    • 8.1.6. Business performance
    • 8.1.7. Key strategic moves and developments
  • 8.2. Cambrex Corporation
    • 8.2.1. Company overview
    • 8.2.2. Key executives
    • 8.2.3. Company snapshot
    • 8.2.4. Operating business segments
    • 8.2.5. Product portfolio
    • 8.2.6. Business performance
    • 8.2.7. Key strategic moves and developments
  • 8.3. Wellona Pharma Private Limited.
    • 8.3.1. Company overview
    • 8.3.2. Key executives
    • 8.3.3. Company snapshot
    • 8.3.4. Operating business segments
    • 8.3.5. Product portfolio
    • 8.3.6. Business performance
    • 8.3.7. Key strategic moves and developments
  • 8.4. Wacker Chemie AG.
    • 8.4.1. Company overview
    • 8.4.2. Key executives
    • 8.4.3. Company snapshot
    • 8.4.4. Operating business segments
    • 8.4.5. Product portfolio
    • 8.4.6. Business performance
    • 8.4.7. Key strategic moves and developments
  • 8.5. Cyclolab
    • 8.5.1. Company overview
    • 8.5.2. Key executives
    • 8.5.3. Company snapshot
    • 8.5.4. Operating business segments
    • 8.5.5. Product portfolio
    • 8.5.6. Business performance
    • 8.5.7. Key strategic moves and developments
  • 8.6. Tocopharm Co. Limited
    • 8.6.1. Company overview
    • 8.6.2. Key executives
    • 8.6.3. Company snapshot
    • 8.6.4. Operating business segments
    • 8.6.5. Product portfolio
    • 8.6.6. Business performance
    • 8.6.7. Key strategic moves and developments
  • 8.7. Roquette Freres
    • 8.7.1. Company overview
    • 8.7.2. Key executives
    • 8.7.3. Company snapshot
    • 8.7.4. Operating business segments
    • 8.7.5. Product portfolio
    • 8.7.6. Business performance
    • 8.7.7. Key strategic moves and developments
  • 8.8. Midas Pharma GmbH
    • 8.8.1. Company overview
    • 8.8.2. Key executives
    • 8.8.3. Company snapshot
    • 8.8.4. Operating business segments
    • 8.8.5. Product portfolio
    • 8.8.6. Business performance
    • 8.8.7. Key strategic moves and developments
  • 8.9. Ligand Pharmaceuticals Incorporated
    • 8.9.1. Company overview
    • 8.9.2. Key executives
    • 8.9.3. Company snapshot
    • 8.9.4. Operating business segments
    • 8.9.5. Product portfolio
    • 8.9.6. Business performance
    • 8.9.7. Key strategic moves and developments
  • 8.10. Cyclo Therapeutics, Inc
    • 8.10.1. Company overview
    • 8.10.2. Key executives
    • 8.10.3. Company snapshot
    • 8.10.4. Operating business segments
    • 8.10.5. Product portfolio
    • 8.10.6. Business performance
    • 8.10.7. Key strategic moves and developments
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦